Tranexamic acid began life as a bleeding-control medicine — then dermatology noticed that it quiets the vascular and inflammatory signalling that keeps melasma switched on. It is now one of the few pigment actives with meta-analysis-level support, available as creams, physician-administered treatments and prescription tablets — three very different tiers sharing one molecule.
WhatsApp Dr Sin Yong →Tranexamic acid blocks plasmin, an enzyme best known in clotting — but plasmin also participates in the skin's ultraviolet response, releasing signals that stir up both blood vessels and melanocytes. In melasma — a disease of overactive pigment cells and vascular, inflamed dermis (see the melasma guide) — damping that pathway quiets the conversation that keeps patches topped up. This upstream mechanism is why TXA helps a condition that humbles ordinary brighteners: it treats melasma's wiring, not just its paint [1,2].
Meta-analyses of randomised controlled trials — the top of the evidence pyramid — support tranexamic acid for melasma, with significant pigment-score improvements across topical and oral routes and a generally favourable safety profile [1,2]. Route matters: creams (typically 2–5%) deliver modest, steady benefit and suit long-term maintenance; physician-delivered intradermal treatment concentrates the active where the disease lives; oral TXA — the strongest tier — is a genuine systemic medicine prescribed and screened by a physician, particularly around clotting-risk history. In every trial worth reading, TXA performs within a programme of photoprotection and topicals — never instead of one.
Its home indication is melasma, where it has become a standard layer of Dr Sin Yong's staged protocol on the melasma treatment pathway — alongside tinted photoprotection, evidence-based topicals and conservative laser toning where indicated. There is also emerging literature in post-inflammatory hyperpigmentation and even post-acne redness. What it is not: a general skin-brightener for anyone without a pigment diagnosis — TXA answers a specific disease mechanism, and using it well starts with confirming you have that mechanism.
Cure melasma — the condition is chronic and relapsing; TXA is control, not cure, and patches return when control lapses. Replace sunscreen — visible-light protection remains the non-negotiable floor beneath every melasma plan. Fix non-melasma browns — sunspots and freckles run on different mechanisms and respond to different tools. And self-prescribe safely at the oral tier — tablets are real medicine with real screening; the pharmacy-counter shortcut is not a shortcut.
“Tranexamic acid treats melasma's wiring rather than its paint — which is exactly why it helps where ordinary brighteners give up.”
— Dr Sin Yong
Leave your name and mobile number and the clinic will contact you directly. No obligation.
Prefer a preliminary view first? You can also WhatsApp a photo of the area for Dr Sin Yong to review before you decide on a visit.
Trials typically measure benefit over 8–12 weeks. Pigment responds in cycles — judge a TXA tier at three months, within a full photoprotection programme.
For diagnosed melasma, quality 2–5% formulations are a reasonable maintenance layer with trial support. For undiagnosed brown patches, diagnosis first — the wrong diagnosis wastes every active.
It is an effective systemic medicine with specific screening — personal or family clotting history above all. That is precisely why it is prescribed and monitored, never casually sourced.
Topical TXA is well tolerated; irritation-driven darkening is uncommon compared with harsher actives. Most 'worse on TXA' stories are melasma's own relapsing nature or unprotected light exposure.
Pigment-type dark circles and PIH have emerging supportive data; vascular and structural circles do not respond. Typing the problem first is the whole game.
In melasma, commonly yes over time — the disease persists beneath control. Maintenance strategy is part of honest planning, not an upsell.